ライフサイエンスコーパス: neurokinin-1 receptor

1 or 2 additional ICC markers (anoctamin-1 and neurokinin 1 receptor).

2 pothesis for their bound conformation at the neurokinin-1 receptor.

3 and 79% of these were immunoreactive for the neurokinin-1 receptor.

4 taining boutons and dendrites possessing the neurokinin-1 receptor.

5 19, the beta(2)-adrenergic receptor, and the neurokinin-1 receptor.

6 giotensin II receptor type 1 and substance P neurokinin 1 receptors.

7 uctive organs to the brain, and they express neurokinin-1 receptors.

8 pinocerebellar tract cells by acting through neurokinin-1 receptors.

9 ng sites and were prevented by inhibition of neurokinin-1 receptors.

10 lls stably transfected with the substance P (neurokinin-1) receptor.

11 but was not affected by spantide I. mRNA for neurokinin-1-receptor-1 (NK-1R) was detected in the norm

12 e formation of DVs by Sub P, implicating the neurokinin-1 receptor, a Gq type of G protein coupled re

13 f CP-96,345 was because of the antagonism of neurokinin-1 receptor, a primary SP receptor.

14 r, microtubule-associated protein-2, and the neurokinin-1 receptor, a target of the neuropeptide, sub

15 in trigeminal subnucleus caudalis by NMDA or neurokinin-1 receptor activation, and whether inhibition

16 NMDA or the specific neurokinin-1 receptor agonist [Sar(9),Met(O(2))(11)]-SP

17 Intrastriatal infusion of the neurokinin-1 receptor agonist GR-73632 induced striatal

18 s in the nucleus ambiguus also expressed the neurokinin 1 receptor and were labeled retrogradely from

19 oline acetyltransferase, substance P and the neurokinin-1 receptor and examined with three-colour con

20 s than 5 nM binding affinities for the human neurokinin-1 receptor and selectivity over the tachykini

21 roduction of NO is modulated by the striatal neurokinin-1 receptors and that this receptor may partic

22 from neurons expressing mu-opioid receptors, neurokinin 1 receptors, and protein kinase C-gamma.

23 Neurokinin-1-receptor antagonism did not alter pneumonia

24 VP release from HNS explants, but neither a neurokinin 1 receptor antagonist [L732,138 (N-acetyl-L-t

25 not evident when cells were treated with the neurokinin 1 receptor antagonist aprepitant before SP st

26 sphamide chemotherapy; and the addition of a neurokinin 1 receptor antagonist for adults who receive

27 in wild-type mice, some pretreated with the neurokinin 1 receptor antagonist SR140333.

28 enase inhibitors), pyrilamine, aprepitant (a neurokinin 1 receptor antagonist), or indomethacin with

29 Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondanset

30 alpha-position of the tryptophan containing neurokinin-1 receptor antagonist [(R)-2-(1H-indol-3-yl)-

31 compound with delta/micro opioid agonist and neurokinin-1 receptor antagonist activities and with a h

32 can be reduced experimentally by intraductal neurokinin-1 receptor antagonist and clinically by use o

33 med a randomized trial of the ability of the neurokinin-1 receptor antagonist aprepitant to reduce sy

34 ogate for stroke volume) was improved in the neurokinin-1 receptor antagonist group during the first

35 E(2) synthesis in the presence of a specific neurokinin-1 receptor antagonist or in cells genetically

36 We aimed to assess the neurokinin-1 receptor antagonist rolapitant, in combinat

37 ina to 0.96 +/- 0.06 (P = 0.001), as did the neurokinin-1 receptor antagonist RP 67580 (n = 12) in th

38 However, the neurokinin-1 receptor antagonist significantly reduced b

39 vival in cecal ligation and puncture sepsis (neurokinin-1 receptor antagonist survival = 79% vs vehic

40 Neurokinin-1 receptor antagonist treatment did not preve

41 Finally, pretreatment with the neurokinin-1 receptor antagonist WIN 51,708 (5mg/kg, ip)

42 vely, relative to controls and the selective neurokinin-1 receptor antagonist WIN-51,708 attenuated t

43 Oral aprepitant, a neurokinin-1 receptor antagonist, is recommended in comb

44 n of SP, which was specifically blocked by a neurokinin-1 receptor antagonist.

45 ic explants is inhibited by the substance P (neurokinin-1) receptor antagonist CP-96,345, indicating

46 gimen of ondansetron, dexamethasone, and the neurokinin-1-receptor antagonist casopitant mesylate was

47 The neurokinin-1-receptor antagonist L-754,030 prevents dela

48 Administration of a neurokinin-1-receptor antagonist to block substance P si

49 udies in ferrets, led us to postulate that a neurokinin-1-receptor antagonist would be an antiemetic

50 led trials also support an expanded role for neurokinin 1 receptor antagonists in patients who are tr

51 his paper will review the characteristics of neurokinin-1 receptor antagonists (NK1-RAs) and the new

52 To review the characteristics of neurokinin-1 receptor antagonists and their potential ro

53 Neurokinin-1 receptor antagonists are effective in reduc

54 Neurokinin-1 receptor antagonists are significantly more

55 Newer antiemetic agents (serotonin and neurokinin-1 receptor antagonists) have increased effica

56 ory to 5-HT3 serotonin receptor antagonists, neurokinin-1 receptor antagonists, and dexamethasone.

57 who will benefit most from prophylaxis using neurokinin-1 receptor antagonists.

58 III of the rat spinal cord that express the neurokinin 1 receptor are densely innervated by peptider

59 Cells with the neurokinin 1 receptor are found in lamina I and lamina I

60 show that mice genetically deficient in the neurokinin-1 receptor are protected from the secretory a

61 ibition caused endosomal retention of the SP neurokinin 1 receptor, beta-arrestins, and Src, resultin

62 in, nitric oxide synthase, somatostatin, and neurokinin 1 receptor but not with neuropeptide Y or cal

63 RVM neurons that were immunoreactive for the neurokinin-1 receptor, but not serotonin.

64 These data show that early activation of the neurokinin-1 receptor by substance P decreases sepsis su

65 The development of the neurokinin-1 receptor-deficient (NK1R(-/-)) mouse permit

66 ar interactions with beta2-agonists into the neurokinin-1 receptor did not lead to increased binding

67 prototypical G protein-coupled receptor, the neurokinin-1 receptor, during its different phases of ce

68 Attaching a single quantum dot to individual neurokinin-1 receptors enabled us to follow with high sp

69 eraction of substance P with the substance P neurokinin-1 receptor expressed by a variety of immune c

70 n the monosynaptic C fiber input to lamina I neurokinin 1 receptor-expressing neurons (1-10 Hz stimul

71 Finally, we show that the neurokinin 1 receptor for substance P is required for SC

72 edullary central chemoreceptor sites contain neurokinin-1 receptor immunoreactivity (NK1R-ir).

73 with spinocerebellar tract cells possessing neurokinin-1 receptor immunoreactivity.

74 e present study, we assessed the role of the neurokinin-1 receptor in the production of striatal 3-ni

75 ed Fos expression and internalization of the neurokinin-1 receptor in these neurons, respectively, in

76 investigating the participation of striatal neurokinin-1 receptors in the methamphetamine (METH)-ind

77 cting though N-methyl-D-aspartate (NMDA) and neurokinin 1 receptors initiate a cascade that evokes re

78 ested that Gln165, His197, and His265 of the neurokinin-1 receptor interact directly with many nonpep

79 Thus, SP-neurokinin-1 receptor interaction may play an important

80 e and formed numerous close appositions with neurokinin-1 receptor-ir pre-Botzinger complex neurons.

81 The neurokinin-1 receptor is expressed by lamina I projectio

82 Substance P, the principal ligand for the neurokinin-1 receptor, is a potent proinflammatory media

83 We also found that activation of neurokinin 1 receptors led to SOCE and activation of SOC

84 The pattern of neurokinin-1 receptor-like immunoreactivity (NK-1Rir) wa

85 We sought to determine whether there are neurokinin-1 receptor-like-immunoreactive (NK-1R-LI) neu

86 n leakage within the dura mater in part by a neurokinin-1-receptor mechanism.

87 Neurokinin-1 receptor mRNA levels in the ipsilateral dor

88 uman colonic epithelial cells overexpressing neurokinin-1 receptor (NCM460 NK-1R) in response to SP s

89 E-1) in controlling substance P (SP) and the neurokinin 1 receptor (NK(1)R) in endosomes of myenteric

90 atory cytokines and of the substance P (SP), neurokinin 1 receptor (NK-1R) in the proximal mesenteric

91 e P (SP), a neuropeptide, interacts with the neurokinin 1 receptor (NK-1R) on immune cells to help co

92 Substance P engages the T cell neurokinin 1 receptor (NK-1R) to enhance IFN-gamma produ

93 SP engages neurokinin 1 receptor (NK-1R) to stimulate cells.

94 monocytic/macrophage THP-1 cells express the neurokinin 1 receptor (NK-1R), and that exposure of thes

95 oinflammatory molecule that interacts with a neurokinin 1 receptor (NK-1R), which is on T cells and h

96 fizer), that blocks the binding of SP to the neurokinin 1 receptor (NK-1R).

97 The neurokinin 1 receptors (NK(1)Rs) and substance P (SP) ha

98 alternative, nonapoptotic pcd induced by the neurokinin-1 receptor (NK(1)R) activated by its ligand S

99 SP) induces endocytosis and recycling of the neurokinin-1 receptor (NK(1)R).

100 and distribution of substance P (SP) and the neurokinin-1 receptor (NK-1) in the SCN and IGL of rat a

101 e may be more than one molecular form of the neurokinin-1 receptor (NK-1), a long and short isoform d

102 vailability of mice genetically deficient in neurokinin-1 receptor (NK-1R(-/-)) allows us to directly

103 mmation via binding to the G-protein-coupled neurokinin-1 receptor (NK-1R) and release of proinflamma

104 Substance P (SP) and the neurokinin-1 receptor (NK-1R) are involved in the develo

105 The substance P (SP)-preferring receptor neurokinin-1 receptor (NK-1R) has two forms: a full-leng

106 hindpaw as a nociceptive stimulus increases neurokinin-1 receptor (NK-1R) mRNA levels in the dorsal

107 SP acts by stimulating the neurokinin-1 receptor (NK-1R) on T lymphocytes and other

108 We have shown that substance P (SP) and its neurokinin-1 receptor (NK-1R) regulate intestinal angiog

109 Substance P (SP) via its neurokinin-1 receptor (NK-1R) regulates several gastroin

110 the hypothesis that substance P (SP) and the neurokinin-1 receptor (NK-1R), both in vitro and in vivo

111 SP) with its G protein-coupled receptor, the neurokinin-1 receptor (NK-1R), have been developed.

112 mmation that had been considered mediated by neurokinin-1 receptor (NK-1R), we sought to determine wh

113 influences immune cell functions through the neurokinin-1 receptor (NK-1R).

114 ion with its cell-surface, G protein-coupled neurokinin-1 receptor (NK-1R).

115 t express the SP receptor, also known as the neurokinin-1 receptor (NK-1r).

116 ression of the proinflammatory and mitogenic neurokinin-1 receptor (NK-1R).

117 chloride secretion, and inflammation via the neurokinin-1 receptor (NK-1R).

118 logic pathways, mainly via its high-affinity neurokinin-1 receptor (NK-1R).

119 gh-affinity receptors for this neuropeptide (neurokinin-1 receptors [NK-1R]), and we have shown that

120 o determine the cellular localization of the neurokinin 1 receptor (NK1), whose preferred ligand is t

121 stance P and microinjection of a substance P-neurokinin 1 receptor (NK1-R) antagonist into the NTS at

122 led an increase of the substance P-inducible neurokinin 1 receptor (NK1-R) in the retina of first, th

123 a interaction with its cognate receptor, the neurokinin 1 receptor (NK1-R), is produced by monocyte/m

124 euronal nitric oxide synthase (nNOS) and the neurokinin-1 receptor (NK1) have been proposed to be inv

125 r substance P (SP) on desensitization of the neurokinin-1 receptor (NK1-R) and on the subcellular dis

126 We have investigated the effect of neurokinin 1 receptor (NK1R) agonists on HEK293 cells tr

127 h neurons in laminae III-IV that express the neurokinin 1 receptor (NK1r) and have dendrites that ent

128 ance P (SP) and hemokinin-1 (HK-1), bind the neurokinin 1 receptor (NK1R) and promote stimulatory imm

129 in the pre-Botzinger complex (pre-BotC), the neurokinin 1 receptor (NK1R) and somatostatin (Sst) pept

130 A subset of preBotzinger Complex (preBotC) neurokinin 1 receptor (NK1R) and somatostatin peptide (S

131 Genetic deletion or antagonism of the neurokinin 1 receptor (NK1R) decreases alcohol intake, a

132 Genetic deletion of the neurokinin 1 receptor (NK1R) has been shown to decrease

133 SP) induces endocytosis and recycling of the neurokinin 1 receptor (NK1R) in endothelial cells and sp

134 Genome editing of the neurokinin 1 receptor (NK1R) in the VTA renders morphine

135 d by spinal opiates; however, when they used neurokinin 1 receptor (NK1R) internalization as an indic

136 Two naturally occurring variants of the neurokinin 1 receptor (NK1R) mediate the effects of SP:

137 d the effects of selective activation of the neurokinin 1 receptor (NK1R) on signaling and traffickin

138 stance P (SP) induces the association of the neurokinin 1 receptor (NK1R) with two classes of protein

139 The neurokinin 1 receptor (NK1R), a G protein-coupled recept

140 We investigated the role of the neurokinin 1 receptor (NK1R), a mediator of behavioral s

141 SP)-induced trafficking and signaling of the neurokinin 1 receptor (NK1R), an important mediator of p

142 ith those in laminae III-IV that express the neurokinin 1 receptor (NK1r), form a major route through

143 ptide substance P (SP) and its receptor, the neurokinin 1 receptor (NK1R), have been proposed as poss

144 dulator substance P (SP) and its target, the neurokinin 1 receptor (NK1R), in the generation and regu

145 Substance P, acting via the neurokinin 1 receptor (NK1R), plays an important role in

146 They were strongly neurokinin 1 receptor (NK1R)-ir and were selectively des

147 and immunological activity via high-affinity neurokinin 1 receptor (NK1R).

148 mina III projection neurons that possess the neurokinin 1 receptor (NK1r).

149 nctions by binding with high affinity to the neurokinin 1 receptor (NK1R).

150 xus (ICC-DMP) of the small intestine express neurokinin 1 receptors (NK1R) and internalize these rece

151 rnalization of mu-opioid receptors (MOR) and neurokinin 1 receptors (NK1R) was measured to assess opi

152 The excitatory actions of the selective neurokinin-1 receptor (NK1R) agonist [Sar9,Met(O2)11]sub

153 Neurokinin-1 receptor (NK1R) and mu-opioid receptor (muO

154 The neurokinin-1 receptor (NK1R) has two naturally occurring

155 (MOR/DOR) and antagonist bioactivity at the neurokinin-1 receptor (NK1R) have been designed and synt

156 up (VRG) contains neurons that are intensely neurokinin-1 receptor (NK1R) immunoreactive (ir).

157 In saline- and CFA-treated rats, neurokinin-1 receptor (NK1R) immunoreactivity was locali

158 nduced trafficking of beta-arrestin1 and the neurokinin-1 receptor (NK1R) in KNRK cells in real time

159 e present study, we examined the role of the neurokinin-1 receptor (NK1R) in the modulation of respir

160 However, 33% of PPG(+) neurons contain neurokinin-1 receptor (NK1R) in the rVRG (126 +/- 12; n

161 Neurokinin-1 receptor (NK1R) mediates down-regulation of

162 e report that substance P (SP) activation of neurokinin-1 receptor (NK1R) stimulates the formation of

163 1) are neuropeptides that signal through the neurokinin-1 receptor (NK1R) to promote inflammation.

164 Substance P neuropeptide and its receptor, neurokinin-1 receptor (NK1R), are reported to present on

165 , protease-activated receptor-2 (PAR(2)) and neurokinin-1 receptor (NK1R), results in drastically dif

166 reBotzinger Complex (preBotC) that coexpress neurokinin-1 receptor (NK1R), SST, and sst2a are critica

167 Our goal was to investigate whether the neurokinin-1 receptor (NK1R)-expressing cells of the ros

168 Neurokinin-1 receptor (NK1R)-expressing neurones that ar

169 n mammals is hypothesized to be generated by neurokinin-1 receptor (NK1R)-expressing neurons in the p

170 According to a recent theory the neurokinin-1 receptor (NK1R)-immunoreactive (ir) neurons

171 type 1 immunity through agonistic binding to neurokinin-1 receptor (NK1R).

172 pidly internalized upon interaction with the neurokinin-1 receptor (NK1R).

173 MORs are coexpressed with neurokinin 1 receptors (NK1Rs) in several regions of the

174 ble-stained with antibodies against MORs and neurokinin 1 receptors (NK1Rs) using immunofluorescence.

175 and its effects are enhanced by SP acting on neurokinin 1 receptors (NK1Rs).

176 Neurokinin-1 receptors (NK1Rs) have been shown to mediat

177 AR-IR does not appear to colocalize with the neurokinin-1 receptor, nor is it localized on astrocytes

178 We examined the effects of mutating the rat neurokinin-1 receptor on endocytosis using 125I-substanc

179 impact of deficiency in SP or its receptor, neurokinin-1 receptor, on wound healing in mouse models.

180 (5) pAkt and pmTOR are expressed in neurokinin 1 receptor-positive neurons in laminae I-III

181 We found that when dorsal horn neurokinin 1 receptor-positive neurons or descending ser

182 Agonist activation of both thrombin and neurokinin-1 receptors promoted a modest increase in [35

183 cetyltransferase, neuropeptide Y, serotonin, neurokinin 1 receptor protein, and somatostatin, was int

184 d with antisera which specifically recognise neurokinin-1 receptor protein and substance P.

185 Thus, endocytosis of the neurokinin 1 receptor relies on several tyrosine-contain

186 The neurokinin-1 receptor signals efficiently through Gq, Gs

187 ons that constitutively express substance P (neurokinin-1) receptors (SPRs).

188 ysis, we identified the presence of mRNA for neurokinin-1 receptor (the receptor for substance P) in

189 Neurokinin-1 receptor treatment at the initiation of sep

190 athetic preganglionic neurons possessing the neurokinin-1 receptor was investigated in the lateral ho

191 (SP), acting at 5-HT(2A/2C), 5-HT(4), and/or neurokinin-1 receptors, was required to maintain inspira

192 npeptide antagonist of the substance P (SP) (neurokinin-1) receptor, was synthesized and shown to hav

193 kinins on platelets are mediated through the neurokinin 1 receptor, which may therefore offer a novel

194 wn that blocking substance P (SP) binding to neurokinin 1 receptor with spantide I prevents Pseudomon

195 ent study examined whether inhibition of the neurokinin-1 receptor with a specific antagonist (CJ-12,

196 f calcitonin gene-related peptide (CGRP) and neurokinin-1 receptors with CGRP(8-37) and RP67580, resp

197 ubstance P peptide, a potent agonist for the neurokinin-1 receptor, with a nitroxide spin probe speci